News

The agreement allows the alliance to establish a combined oncology sales organization in key markets in advance of the potential launch of avelumab-based treatment regimens in the future.

As part of the deal, Neurotrope will pay WCT about $300,000 for the services and related third-party costs. In early second quarter of 2015, Neurotrope plans to submit

RTOG Foundation’s partner NRG Oncology will be responsible for conducting the pivotal Phase II/III anal cancer trial of concurrent chemotherapy of mitomycin C/5FU and radiation therapy (CCRT) compared

If approved, this will become the fourth indication for Pradaxa (dabigatran etexilate mesylate). The sNDA is based on the results of two randomized, double-blind Phase III trials, RE-NOVATE

As part of the deal, Sanofi Pasteur will have an option to acquire certain worldwide rights to use VBI’s LPV technology in its vaccines to provide improved stability.

Data from this trial supported the initiation of the ongoing, pivotal Phase II METRIC trial in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB). Glembatumumab

FOLFIRI is an irinotecan-based chemotherapy regimen, which is frequently used in first-line colorectal cancer treatment in Europe. The approval from the new indication is based on data from

The deal will give BMS exclusive access to uniQure’s gene therapy technology platform for the development of new treatments. The companies will collaborate on up to ten targets,

Demcizumab is a humanized monoclonal antibody that inhibits Delta-Like Ligand 4 (DLL4) in the Notch signaling pathway. Under the deal, OncoMed’s demcizumab will be tested in combination with